A Food and Drug Administration advisory committee last week recommendedthe approval of FS069, a second-generation ultrasound contrastagent developed by Molecular Biosystems of San Diego. The productnow awaits a final decision by the FDA, which could come
A Food and Drug Administration advisory committee last week recommendedthe approval of FS069, a second-generation ultrasound contrastagent developed by Molecular Biosystems of San Diego. The productnow awaits a final decision by the FDA, which could come in thenext several months.
The action by the Radiology Device Advisory Panel comes onlymonths after FS069's premarket approval application was filedby MBI and its U.S. marketing partner for the agent, Mallinckrodtof St. Louis (SCAN 11/6/96). FS069's path through the FDA approvalprocess has been considerably shorter than MBI's previous contrastagent, Albunex, which underwent nearly four years of PMA reviewbefore it was finally approved by the agency in 1994 (SCAN 8/31/94).
Industry analysts believe that FS069 has much more potentialthan Albunex, which was the first ultrasound contrast agent onthe U.S. market. Sales of Albunex have been disappointing, dueto its short duration and the complexity required to handle theproduct.
FS069 is designed to enhance visualization of endocardial borderdelineation and left ventricular opacification during echocardiographyexams. This capability is important in diagnosing regional andglobal wall-motion abnormalities, which may be a measure of theseverity of coronary artery disease. The advisory committee alsorecommended approval of FS069 for enhancing Doppler signals. MBIplans to pursue additional cardiac imaging capabilities for FS069,including myocardial perfusion and enhancement of liver and kidneyultrasound imaging.
In making its decision, the advisory panel took the positionthat the data supporting the safety and effectiveness of FS069were so compelling that the agent was recommended to the FDA withoutconditions, including no postmarket surveillance follow-up.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.